New clinical trials reveal the new SGLT2 inhibitor lowers HbA1c as well as sitagliptin….
In a recent clinical trial involving the investigational drug empagliflozin, Roden et. al., randomized 899 patients to receive either 10 mg or 25 mg of empagliflozin, 100 mg sitagliptin once daily, or placebo for 24 weeks. The primary endpoint was a change in HbA1c. Researchers discovered that reductions in HbA1c were comparable between the two treatment groups of empagliflozin and sitagliptin.
Patients with HbA1c of 8.5% or higher had a greater reduction in HbA1c values compared with those taking sitagliptin. Researchers also noted that patients in the empagliflozin group had better reductions in systolic and diastolic blood pressure, including more weight loss, in comparison to the DPP-4 inhibitors.
There are more drug-related adverse events with the SGLT2 inhibitors compared to the other treatment groups. More patients (12.7%) on empagliflozin experienced urinary tract infections, compared to 8.5% in those treated with sitagliptin, and more genital infections were noted with the SGLT2 inhibitors.
- SGLT2 inhibitor as effective as DPP-4 inhibitor in reducing HbA1c.
- Empagliflozin reduces SBP and DBP more than sitagliptin.
- Empaglifozin causes more weight loss than sitagliptin.
The Lancet Diabetes & Endocrinology, September 2013